Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nemaura’s SugarBEAT Non-Invasive CGM Earns CE Mark

Executive Summary

SugarBEAT is a non-invasive, needle-free, disposable adhesive skin-patch connected to a rechargeable transmitter. The company says it is the world’s first non-invasive continuous glucose monitor.

You may also be interested in...



Start-Up Spotlight: GlucoModicum Plans To Disrupt Glucose Monitoring With Painless Wearable

Medtech Insight spoke to the CEO of GlucoModicum to learn more about its approach to developing a pain-free, convenient glucose monitor for people managing their diabetes.

Global Device Approvals Snapshot: 28 May-3 June 2019

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week’s approvals include the US FDA's approval of a panel-track supplement for TransMedics' OCS Lung system to preserve donor lungs that would not be salvageable using a traditional cold static system.

Results Recap: Post-Market Results From Avinger's Pantheris Peripheral OCT System; Nemaura Announces sugarBEAT CGM Results

This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from Meddevicetracker.com, includes preliminary analysis of results from Avinger's SCAN clinical study, a 12-patient, 240-image post-market study of Avinger's Pantheris optical coherence tomography in the peripheral arteries and results of an 18-patient early-feasibility study showing Nativis' Voyager device is safe for treatment of recurrent glioblastoma.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT125192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel